Insights from 2025 ASCO® GI Annual Meeting
Video Player is loading.
10 seconds
Playback speed
ASCO® GI 2025 Insights: Camrelizumab + Rivoceranib vs. Sorafenib for 1L Unresectable HCC of Viral and Non-Viral Etiology - Ph3 CARES-310 Trial
By
Insights from 2025 ASCO® GI Annual Meeting
FEATURING
Rachna Shroff
By
Insights from 2025 ASCO® GI Annual Meeting
FEATURING
Rachna Shroff
Comments 0
Login to view comments.
Click here to Login
